{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-078451","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2024-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.214234+00:00","generated_at":"2026-05-31T22:34:20.449144+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Carisma reports 75% ctDNA reduction in HER2 3+ patients in Phase 1 CT-0508 trial","bullets":["75% (6/8) evaluable HER2 3+ patients had ctDNA reduction (median 81%, range 33%-93%); no reduction in 5 HER2 2+ patients.","Best overall response: stable disease in 44% (4/9) of HER2 3+ patients; all HER2 2+ patients had progressive disease.","Phase 1 CT-0508 enrollment halted April 2024; all patient activities completed as of July 2024.","Company expects clinical data updates in Q3 2024 and initial Phase 1 data for follow-on CT-0525 in Q4 2024.","Preliminary data supports mechanism of action and potential for repeat dosing with CT-0525 in HER2 overexpressing cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-078451","json":"https://secwatch.observer/filing/0001104659-24-078451.json","markdown":"https://secwatch.observer/filing/0001104659-24-078451.md","text":"https://secwatch.observer/filing/0001104659-24-078451.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924078451/0001104659-24-078451-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924078451/tm2419051d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:34:20.449144+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}